// App-Quantinova.ai

TPS4153 : Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Researchers

Presenter

  • Dung T. Le

Principal Investigators

  • Todd S. Crocenzi

  • Jennifer N. Uram

  • Eric R. Lutz

  • Daniel A. Laheru

  • Elizabeth A. Sugar

  • Robert H. Vonderheide

  • George A. Fisher

  • Andrew H. Ko

  • Aimee Murphy

  • Katherine McDougall

  • Sandy Ferber

  • Dirk G. Brockstedt

  • Elizabeth M. Jaffee

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • Providence Cancer Center, Portland, OR

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Departments of Epidemiology and Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Aduro Biotech, Inc., Berkeley, CA

  • Array Biostatistics, LLC, Evanston, IL

Locations

  • United States

Companies

  • Aduro Biotech, Inc.

  • Array BioPharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Carbohydrate antigen 19-9

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Nivolumab

  • CRS-207

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02243371

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved